VRDN vs XENE Stock Comparison
VRDN currently leads XENE in this stock comparison, with AIQ scores of 58 vs 49. The clearest difference is momentum, while XENE has the stronger quality profile.
What is the main difference between VRDN and XENE?
VRDN leads the current stock comparison as Viridian Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Viridian Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
VRDN leads
VRDN leads by 9 AIQ points, primarily on Momentum. Wall Street currently favors XENE on target upside.
Fragile: 2 of 5 evidence groups support VRDN, and its current signal state is conflicted.
Viridian Therapeutics, Inc.
Xenon Pharmaceuticals Inc.
The Algovestiq AIQ Score currently favors VRDN over XENE, 58 versus 49 as of Nov 15, 2026. VRDN's advantage is driven primarily by stronger momentum, while XENE holds the stronger quality profile. VRDN also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XENE. 2 of 5 covered evidence groups favor VRDN today, and the comparison is rated Fragile on stability: only 2 of 5 covered evidence groups agree. VRDN lead: Stable — the AIQ differential has held near 9 points over 30 sessions.
Compare Viridian Therapeutics, Inc. and Xenon Pharmaceuticals Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare VRDN and XENE against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum91 vs 33VRDN +58
- Quality41 vs 68XENE +27
- Risk Resilience46 vs 49Even
2 of 5 evidence groups favor VRDN. VRDN’s edge is concentrated in momentum; XENE keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 9 active signals are unchanged.
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.47x)
VRDN's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — VRDN and XENE both carry a full feed there.
The central trade-off
VRDN (Viridian Therapeutics, Inc.): the stronger current systematic profile, led by momentum.
XENE (Xenon Pharmaceuticals Inc.): the counter-case, on quality, fundamentals, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
VRDNVRDN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
VRDNVRDN on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
VRDNVRDN on the Momentum factor, by 58 points.
Lower downside
XENEXENE carries the lower 1-month annualized volatility.
Analyst upside
XENEXENE on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors VRDN, analyst targets favor XENE. That disagreement is the most useful thing on this page.
| Measure | VRDN | XENE | Note |
|---|---|---|---|
| Implied upside to target | +31.2% | +67.6% | XENE has more room |
| Target dispersion | +12.3% | +64.8% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 17 | 18 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor VRDN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | VRDN | 58 vs 49 |
| Fundamentals | XENE | TTM ROE -17.4% vs -9.6% |
| Valuation | Not covered | Not covered |
| Technicals | VRDN | Price vs 50-day 35.7% vs -1.6%; vs 200-day 43.2% vs -22.6% |
| Risk Resilience | Even | Risk Resilience 46 vs 49 |
| Analyst expectations | XENE | Target upside 31.2% vs 67.6% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VRDN and XENE and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 9 points.
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VRDN.
How the comparison changed
120 daily snapshots · May 27 – Nov 13VRDN lead: Stable — the AIQ differential has held near 9 points over 30 sessions.
- Today
- VRDN +9
- 58 vs 49
- 7 sessions ago
- VRDN +7
- 56 vs 49
- 30 sessions ago
- VRDN +10
- 56 vs 46
- 90 sessions ago
- XENE +26
- 47 vs 73
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
5 bullish / 2 bearish / 2 neutral, conflicted
Only VRDN
- Golden Cross Active — bullish, trend, long horizon (5.52%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
0 bullish / 3 bearish / 2 neutral
Only XENE
- Death Cross Active — bearish, trend, long horizon (27.10%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Downtrend Structure Active — bearish, trend, long horizon
Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, Low Volume Rally Warning.
VRDN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.28%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1XENE closes the Momentum gap — currently 58 points behind, the largest single contributor to VRDN's edge.
- 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3VRDN's conflicting signal state resolves bearish — it currently carries 5 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
XENE leads on balance| Metric | VRDN | XENE |
|---|---|---|
| Revenue growth (YoY) | 89.7% | 0% |
| EPS growth (YoY) | 22.9% | 0% |
| Gross margin | 93% | 0% |
| Operating margin | -17.8% | 0% |
| Return on equity (TTM) | -17.4% | -9.6% |
| Debt to equity | 0.42 | 0.01 |
Performance
VRDN leads 6 of 6 windows| Metric | VRDN | XENE |
|---|---|---|
| 1 week (5 sessions) | 8.4% | 3.3% |
| 1 month (20 sessions) | 62.2% | 20.9% |
| 3 months (63 sessions) | 33.7% | -35.1% |
| 6 months (126 sessions) | 83.5% | -25.6% |
| Year to date | -0.8% | -9.7% |
| 1 year (252 sessions) | 6.7% | 2% |
Technicals
VRDN has the stronger structure| Metric | VRDN | XENE |
|---|---|---|
| RSI (14) | 77.3 | 54.9 |
| ADX (14) | 51 | 24 |
| Price vs 50-day | 35.7% | -1.6% |
| Price vs 200-day | 43.2% | -22.6% |
| Volatility (1M, annualized) | 69.7% | 38% |
Risk
Split| Metric | VRDN | XENE |
|---|---|---|
| Beta | 1.14 | 0.86 |
| Sharpe ratio | 0.43 | 0.27 |
| Sortino ratio | 0.62 | 0.48 |
| Max drawdown | -60.6% | -52.8% |
| Current drawdown | -8.6% | -43% |
| Annualized volatility | 72% | 68.1% |
| Value at risk (95%) | -4.2% | -3.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, VRDN or XENE?
On the Algovestiq AIQ Score, VRDN is the stronger of the two as of Nov 15, 2026, scoring 58 against XENE's 49. The edge comes from momentum. XENE is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is VRDN or XENE the better buy right now?
VRDN carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 5 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor VRDN over XENE?
The composite weights Quality, Value, Momentum and Risk Resilience. VRDN leads Momentum by 58 points; XENE leads Quality by 27 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, VRDN or XENE?
Analyst price targets imply +31.2% upside for VRDN and +67.6% for XENE, so the Street currently favors XENE. That points the opposite way to the AIQ Score, which favors VRDN. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, VRDN or XENE?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, VRDN or XENE?
VRDN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, VRDN or XENE?
VRDN on the Momentum factor, by 58 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, VRDN or XENE?
XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is VRDN more profitable than XENE?
XENE leads on the comparable margin measures — gross margin 93% vs 0%; operating margin -17.8% vs 0%; ttm roe -17.4% vs -9.6%.
Is VRDN's lead over XENE getting stronger or weaker?
VRDN lead: Stable — the AIQ differential has held near 9 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the VRDN vs XENE verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 58 points behind, the largest single contributor to VRDN's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; VRDN's conflicting signal state resolves bearish — it currently carries 5 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about VRDN and XENE?
VRDN: 5 bullish / 2 bearish / 2 neutral, conflicted. XENE: 0 bullish / 3 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VRDN is Golden Cross Active (bullish, long horizon). On XENE it is Death Cross Active (bearish, long horizon).
Compare VRDN and XENE with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.